BiotechTube
Home/Pipeline/Varenicline/Bupropion Combination

Varenicline/Bupropion Combination

Alcohol Use Disorder (AUD)

Phase 2Active

Key Facts

Indication
Alcohol Use Disorder (AUD)
Phase
Phase 2
Status
Active
Company
Sobrera Pharma

About Sobrera Pharma

Sobrera Pharma is a clinical-stage biotech targeting the large, underserved market of Alcohol Use Disorder with a novel combination therapy of varenicline and bupropion. The company has successfully completed a Phase II trial showing statistically significant reductions in alcohol consumption, positioning it for potential Phase III development. As a private company, Sobrera is advancing its lead program while seeking partnerships and funding to address a significant global health burden.

View full company profile

Therapeutic Areas

Alcohol Use DisorderAddiction

Other Alcohol Use Disorder (AUD) Drugs

DrugCompanyPhase
KT-110Kinnov TherapeuticsPhase 2
KT-110 (New Galenic Form)Kinnov TherapeuticsFormulation Testing
TMP-301Tempero BioPhase 1
iSTEP-NAkyso TherapeuticsPre-clinical
ANS-858Amygdala NeurosciencesPreclinical
TNX-102 SLTonix PharmaceuticalsPhase 2
SVN-015Solvonis TherapeuticsPre-clinical